PerspectiveKidney Disease

Rituximab’s New Therapeutic Target: The Podocyte Actin Cytoskeleton

See allHide authors and affiliations

Science Translational Medicine  01 Jun 2011:
Vol. 3, Issue 85, pp. 85ps21
DOI: 10.1126/scitranslmed.3002429

You are currently viewing the abstract.

View Full Text


Therapeutic off-target activities are well recognized for small-molecule drugs. In contrast, monoclonal antibodies (mAbs) traditionally are believed to act specifically and lack off-target therapeutic effects. In this issue of Science Translational Medicine, Fornoni et al. show therapeutic benefit, through an off-target–mediated mechanism, of the mAb drug rituximab in recurrent focal segmental glomerulosclerosis (FSGS) after kidney transplantation. These data shed new light on FSGS pathogenesis and suggest new therapeutic interventions for proteinuric diseases.


  • Citation: A. C. Chan, Rituximab’s New Therapeutic Target: The Podocyte Actin Cytoskeleton. Sci. Transl. Med. 3, 85ps21 (2011).

View Full Text